[Advances and difficulties of present-day treatment of acute myeloblastic leukemia]

The success in acute myeloblastic leukemia (AML) treatment for the last 10 years has been referred to growing intensity of chemotherapy. The efficacy of treatment has been assessed in 56 patients under 60 years of age. Double induction of remission according to the scheme TAD-9 (2-day administration of cytosar) and consolidation by large-dose cytosar (1 g/m2) with rubomycin have increased the frequency of 2-year recurrence-free running from 13 to 35%. Resistance to treatment was absent. Maintenance prolonged total and recurrence-free survival. Mycosis and hepatitis were factors responsible for inadequate intensity of chemotherapy. These need more advanced prevention. The intensive double induction and consolidation did not raise general toxicity and immediate lethality compared to standard regimens which proved inferior to the proposed treatment.